A Phase 2 study of JNJ-90301900 with chemoradiation | Clinical Research Studies Listing

Recruiting

18-99 years

All

Phase N/A

1 Location

Brief description of study

A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: Between 18 Years - 99 Years
Gender: All

TBD

Updated on 13 Nov 2024. Study ID: 857171

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Phase 2 study of JNJ-90301900 with chemoradiation and durvalumab for non-small cell lung cancer (CONVERGE)

Brief description of study

Eligibility of study

Find a site

What happens next?

Interested in the study